Trials / Completed
CompletedNCT00219011
"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure
A Twelve-week, Randomized, Double-blind, Multi-center, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Aliskiren 150 mg When Added to Standard Therapy in Hypertensive Patients With Stable Heart Failure
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 280 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to determine if patients, who have both high blood pressure and heart failure and are currently receiving drug treatment for heart failure, have an improvement in their heart failure signs and symptoms and other indicators of heart failure after being treated with aliskiren on top of their current heart failure treatment. Aliskiren is an investigational drug; its safety will also be evaluated in this trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aliskiren |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2005-09-22
- Last updated
- 2017-05-17
Locations
2 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT00219011. Inclusion in this directory is not an endorsement.